REDWOOD CITY, Calif., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology
company dedicated to delivering innovative, biometric remote monitoring solutions, today announced it is actively building out its
sales force and pursuing pilot sites in preparation for the launch of its Bioflux device. With manufacturing in place and initial production underway, the company has
shifted its focus to sales and marketing. The company had built out its sales management team and is now building its sales force
to provide the additional capacity required for its anticipated business growth in 2018.
“We are looking forward to carrying our positive momentum into 2018 as we prepare to launch Bioflux,” said Waqaas Al-Siddiq,
Biotricity Founder and CEO. To ensure the delivery of outstanding results, Biotricity is conducting a rigorous hiring process to
find salespeople with advanced medical and/or cardiac sales experience. “We foresee creating a sales team of 12 staff in Q1 2018,
and expanding our pilot sites to accelerate our market entry,” said Al-Siddiq.
The company has already piloted at several sites and is pursuing additional sites in preparation for the launch of Bioflux. With
pilots underway, Biotricity is aggressively going after leads and conducting demos.
To learn more, visit www.biotricity.com or follow on
Twitter: @biotricity_inc Facebook: www.facebook.com/biotricity/ or
LinkedIn: www.linkedin.com/company/biotricity-measuring-vitals
About Biotricity Inc.
Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the
medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement.
Biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the
hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of
innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements.
Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally
identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,”
“believe,” “intend,” “seek,” or “project” or the negative of these words or other variations on these words or comparable
terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of
management for future operations, including plans or objectives relating to the design, development and commercialization of
Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings
(including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the
Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the
assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking
statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized
because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions
and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual
results and the timing of certain events and circumstances may differ materially from those described by the forward-looking
statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the
forward-looking statements or cause actual results to differ materially from expected or desired results may include, without
limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with
the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand
the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product
diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and
the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described
in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in
order to reflect any event or circumstance that may arise after the date of this release.
Media Contacts
McCoin & Smith Communications Inc.
Chris McCoin,
Chris@mccoinsmith.com, 508-429-5988
Richard Smith,
rick@mccoinsmith.com, 978-433-3304
Investor Relations:
Biotricity Inc.
1-800-590-4155
investors@biotricity.com
